（精）杰诺维DPP-4抑制剂的同与异.ppt

We included studies in this meta-analysis if (1) they were RCTs comparing DPP4 inhibitor monotherapy in 1 arm to other oral antitype 2 DM agents (other than DPP4 inhibitors) in the comparator arm, (2) duration of treatment was 24 weeks, and (3) reported data on adverse CV side effects of DPP4 inhibitor therapy (death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke, heart failure, and arrhythmias).The quality of included articles was further assessed。 The primary end point was development of adverse CV events defined as death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke and arrhythmias (including atrial fibrillation, supraventricular tachycardia, or palpitations), and heart failure. * We included studies in this meta-analysis if (1) they were RCTs comparing DPP4 inhibitor monotherapy in 1 arm to other oral antitype 2 DM agents (other than DPP4 inhibitors) in the comparator arm, (2) duration of treatment was 24 weeks, and (3) reported data on adverse CV side effects of DPP4 inhibitor therapy (death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke, heart failure, and arrhythmias).The quality of included articles was further assessed。 The primary end point was development of adverse CV events defined as death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke and arrhythmias (including atrial fibrillation, supraventricular tachycardia, or palpitations), and heart failure. * 结果显示，捷诺维总体安全性良好，与非暴露组相比无差异。 由于捷诺维是葡萄糖依赖性的降糖机制，低血糖发生率与非暴露组相比更低。 对体重的影响也是中性。 2007年，捷诺维荣获了有“医药界诺贝尔奖”之称的Prix Galien （艾伦奖)最佳药物奖 Prix Galien奖是用于表彰可实质改善治疗效果，带给患者利益的创新药物的荣誉奖项，激励那些药学领域著名的研究成果 * * 捷诺维超过95个国家和地区上市，一年超过3300万张处方。 2011年成为全球第一大口服品牌降糖药。 * 维格列汀对DPP-4酶的抑制作用 0 20 40 60 80 100 0 4 8 12 16 20 24 第1天 安慰剂 维格列汀 50 mg qd 维格列汀 100 mg qd 对DPP-4 的抑制, %b C. F. Deacon, Obesity and Metabolism 13: 7–18, 2011 内部交流材料 沙格列汀对DPP-4酶的抑制作用 Tahrani AA et al. Adv Ther. 2009;26(3):249–262.